ARID1A and cancer: Although contextual differences exist across cancer types, the above-mentioned therapeutics identified with bioinformatics or screening strategies [48] are promising alternatives to treat tumors with synthetic lethal strategies in ARID1A, SMARCA4, KDM6A, KMT2C, or KMT2D with GI cancers as a field of future research interest (Figure 2).